According to an Exact Sciences release, Pfizer has signed an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Reportedly, the two companies will each invest $24 million next year to promote Cologuard.

In a Reuters report, Exact Sciences CEO Kevin Conroy says Pfizer will also receive 50% of gross profit above an agreed-upon baseline. The Madison company will continue marketing the product.